Compare prices and buy Wolverine Blend from 45 research peptide vendors - also called suppliers or sources. Updated daily.
TB-500 + BPC-157
A two-peptide research blend pairing BPC-157, a 15-amino-acid fragment of a gastric protein, with TB-500, sold as either full-length thymosin beta-4 or its seven-residue 17-23 fragment depending on the vendor. The two act through unrelated mechanisms, and the pairing has not been evaluated in a controlled human trial. Vendors ship the two in equal amounts. For research purposes only.
For research purposes only. Not medical advice.
The Wolverine Blend is a fixed combination of two research peptides in a single vial: BPC-157 and TB-500. It is a mixture rather than a distinct chemical entity, and no regulatory or pharmacopeial body recognizes "Wolverine" as a substance. The name is vendor branding, an allusion to the comic-book character known for rapid healing.
The composition is unusually consistent for a blend. Every vendor indexed here whose listing states the split states it as 1:1: a 10 mg vial is 5 mg of each peptide, a 20 mg vial is 10 mg of each, and 12 mg and 30 mg vials keep the same split. In GLOW and KLOW, the GHK-Cu component typically runs several times the load of everything else.
BPC-157 is a synthetic 15-amino-acid sequence (GEPPPGKPADDAGLV) corresponding to a fragment of a protein isolated from human gastric juice. The mechanisms proposed for it (modulation of nitric oxide signaling, upregulation of VEGFR2, activation of the FAK-paxillin pathway) come from cell-culture and rodent studies.
Thymosin beta-4 is a 43-residue actin-sequestering protein present in nearly all human cells. By binding monomeric G-actin it shifts cytoskeletal assembly, which in laboratory wound models has been associated with cell migration, angiogenesis and re-epithelialization.
The two share no sequence, no origin and no mechanism, so the pairing is a market convention rather than a pharmacological one. BPC-157 has not completed a controlled human trial. Full-length thymosin beta-4 has, as the RGN-259 eye drop in randomized, placebo-controlled dry eye trials (the ARISE program). The fragment has not, and no controlled trial has tested the combination.
"TB-500" covers two molecules: full-length thymosin beta-4, CAS 77591-33-4, indexed here as TB-500 Thymosin Beta-4, and the N-acetylated seven-residue TB-500 Frag 17-23, CAS 885340-08-9. Blend listings name a "TB-500" component without saying which. The CAS number or molecular formula on the certificate of analysis is the only reliable check, and it is a price question as much as an identity one.
PeptideScouter records a blend's size as the total peptide content of the vial, summed across its components. A 20 mg Wolverine vial holds 10 mg of each peptide, so the correct benchmark for its price per milligram is a 1:1 weighted average of the two component prices, not the price of a 20 mg single-peptide vial.
Because the split is even, neither component dominates that average, but which TB-500 the vial holds changes the benchmark, since the fragment and the full chain are indexed as separate rows. A blend that looks cheap next to a single-peptide vial is usually just a bigger vial.
Neither component is an FDA-approved drug, and the blend as sold is not a compounded prescription product.
The blend itself was not reviewed, because nominations to the 503A list are per substance and per proposed indication. Full-length thymosin beta-4 was never the substance at any step: the Category 2 entry, its removal and the vote all concerned the seven-residue fragment. The recommendation is advisory either way: the list changes only through notice-and-comment rulemaking. Our writeup of the July 2026 PCAC vote covers all seven substances heard that week.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
The Wolverine Blend is a fixed 1:1 combination of BPC-157 and TB-500 in a single vial. A 10 mg vial contains 5 mg of each peptide and a 20 mg vial contains 10 mg of each. Every vendor indexed here whose listing states the split states it as 1:1. Wolverine is a vendor trade name rather than a scientific designation. Material sold by research peptide vendors is offered for laboratory use only, not for human consumption.
A CAS Registry Number identifies a single chemical substance, and this blend is a mixture of two of them. The components carry their own: BPC-157 is 137525-51-0, full-length thymosin beta-4 is 77591-33-4, and the seven-residue TB-500 fragment is 885340-08-9. A certificate of analysis for a blend should report each component separately, which is also the only way to confirm what is actually in the vial.
Vendors usually do not say. The name TB-500 is used for two different molecules: full-length thymosin beta-4, a 43-amino-acid protein, and an N-acetylated seven-residue fragment covering residues 17 to 23 of it. Blend listings typically name a TB-500 component without stating which one, and the substance the FDA reviewed under that name in 2026 was the fragment. The CAS number or molecular formula on the certificate of analysis is the only reliable way to tell, and it matters for price comparison as well as identity.
Comparing them takes care, because PeptideScouter records the blend's size as the total peptide content of the vial. A 20 mg Wolverine vial holds 10 mg of each component, so its price per milligram is not comparable to that of a 20 mg single-peptide vial. The like-for-like benchmark is the average of the two component prices, not either one alone, and it depends on which TB-500 the vial holds. The price table on this page lists the blend's own listings, and each component's live prices are on its own page.
No. The FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 and the seven-residue TB-500 fragment as separate substances at its July 23-24, 2026 meeting, each under its own nomination and for a different proposed indication (ulcerative colitis for BPC-157 and wound healing for the fragment), recommending each by 8 votes to 6 with one abstention. No combination product, and no full-length thymosin beta-4, was before the committee. Those votes are advisory, the FDA changes the Section 503A bulk drug substances list only through notice-and-comment rulemaking, and none of it applies to research-grade material sold by peptide vendors.
Wolverine Blend is sold by 45 research peptide vendors indexed on PeptideScouter, with 115 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
44 of the 45 indexed vendors currently have Wolverine Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Renova Peptides currently lists Wolverine Blend at $2.15/mg, the lowest listed price across 45 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.93/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 45 vendors listing Wolverine Blend publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.15/mg listed to $1.93/mg at Renova Peptides. Each vendor's code is shown beside its price in the table above.
Wolverine Blend ranges from $2.15/mg to $11.99/mg across 115 listings from 45 research peptide vendors, normalized to USD per milligram and refreshed daily.
45 research peptide vendors currently list Wolverine Blend on PeptideScouter, with 44 in stock right now. We track 115 listings across size and kit variants.
